Piotr Swat | Lightrocket | Getty Pictures
As its high-margin compounded GLP-1 enterprise evolves, Hims & Hers Well being could also be discovering a brand new alternative in peptides.
Shares of the telehealth firm jumped Thursday after Well being and Human Providers Secretary Robert F. Kennedy Jr. introduced Wednesday that the FDA plans to convene a Pharmacy Compounding Advisory Committee assembly to evaluate peptides for potential inclusion on the 503A bulk listing, a designation that permits medicine to be compounded on a person prescribed foundation slightly than mass producing.
For Hims, the larger story is how increasing compounding for peptides might unlock new income streams because it directs members towards branded slightly than extra worthwhile compounded GLP-1 medicine. The telehealth firm has been constructing towards a peptide enterprise for years.
Peptides are brief chains of amino acids — consider them as small constructing blocks of proteins — which might be being explored for a variety of well being and wellness makes use of. They’re controversial as a result of scientific proof on their long-term security and effectiveness is proscribed, and their manufacturing stays largely unregulated.
Hims & Hers made a big transfer into the house in February 2025 when it acquired a California-based peptide facility. On the time, CEO Andrew Dudum known as peptide demand “future-facing innovation.”
“Many use circumstances have but to be launched,” mentioned Dudum. “Peptide innovation is on the forefront of so many classes we’re excited to begin providing.”
Following Kennedy’s announcement on Wednesday, Hims Chief Medical Officer Dr. Patrick Carroll applauded the information as a transfer away from the “grey market,” saying the objective is to convey peptide remedy into regulated, physician-led care.
“Our medical group believes sure peptide therapies maintain significant potential in serving to People dwell more healthy lives, and we’re actively exploring develop entry in a approach that shall be aligned with FDA steerage,” Carroll mentioned.
Leerink Companions known as the information that the FDA will evaluate peptides for the compounding listing a optimistic end result that might give Hims a clearer regulatory path to scale peptide therapies. Even so, the agency mentioned it should take time for peptides to spice up the corporate’s backside line.
“This could not instantly translate into income, however would seemingly be a development avenue that HIMS would push arduous on,” mentioned Leerink analyst Michael Cherny, who has a hold-equivalent score on the inventory and a $25 value goal. The inventory was buying and selling at round $26 a share Thursday.
For now the chance continues to be early, and medical proof supporting many peptide therapies continues to be restricted.
Of the dozen peptides listed by Kennedy for consideration on the compounding bulk listing, one — MK-677 — is commonly handled as an unlawful drug when bought for human consumption. The expansion hormone has additionally been banned by the World Anti-Doping Company.
Different peptides on the listing, akin to GHK-Cu and Semax, that are used for beauty or cognitive enhancement, are typically considered as much less controversial, however nonetheless lack sturdy scientific backing.
Kennedy — who has supported many medical remedies and meals choices exterior of these backed by mainstream science — was requested about his plans for increasing peptide therapies throughout a Home Methods and Means Committee listening to Thursday.
“Peptides weren’t presupposed to be regulated,” Kennedy mentioned, arguing the Biden administration restricted using peptides resulting from security issues that he considers unfounded.
The FDA course of is simply starting, and the July assembly shall be advisory solely, so change isn’t anticipated to be speedy.
Even so, buyers are already specializing in what replaces GLP-1 as a development driver for Hims, and peptides are rising as one of many clearest candidates to date.